marginally significantP = 0.06
Hypertension in the very elderly trial (HYVET) post hoc analysis showed that frail older individuals could benefit from antihypertensive treatment compared with placebo ( 24 ), and the SPRINT subgroup study showed that older adults ≥ 75 years of age could benefit from intensive antihypertensive therapy compared with standard treatment, regardless of whether they were frail, albeit marginally significant ( P = 0.06).